STOCK TITAN

X4 Pharmaceuticals, Inc. - XFOR STOCK NEWS

Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) is a late-stage clinical biopharmaceutical company committed to the development of novel therapeutics aimed at improving immune cell trafficking and reversing immune suppression. The company's core focus is on treating rare diseases and conditions resulting from immune system dysfunction, including cancer and genetic primary immunodeficiency diseases.

X4’s lead clinical candidate, mavorixafor, is a selective, small-molecule antagonist of the chemokine receptor CXCR4. Designed as an oral, once-daily therapy, mavorixafor targets immune cell mobilization and has shown promising results in clinical trials. It is currently under priority review by the FDA for the treatment of WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare primary immunodeficiency. The company’s recent NDA submission is supported by positive results from the global, pivotal 4WHIM Phase 3 clinical trial, which demonstrated mavorixafor's ability to reduce infection rates and improve immune cell counts without serious adverse events.

In addition to mavorixafor for WHIM syndrome, X4 is advancing its pipeline with ongoing investigations for mavorixafor in chronic neutropenic disorders and other immunodeficiencies. The company has also initiated preclinical development of other CXCR4 antagonists, including X4P-002 and X4P-003, to address different properties and mechanisms within the immune system.

Headquartered in Boston, Massachusetts, with a research center in Vienna, Austria, X4 leverages its deep understanding of CXCR4 biology to innovate and bring transformative therapies to patients with limited treatment options. The company's mission is driven by a commitment to improve the lives of those affected by rare and severe immune diseases through rigorous scientific research and strategic investment in its proprietary pipeline.

For more updates and detailed information, visit X4 Pharmaceuticals.

Rhea-AI Summary

X4 Pharmaceuticals announced the issuance of inducement awards to new employees under the 2019 Inducement Plan, consisting of options to purchase 605,349 shares of X4's common stock. The options have a ten-year term, with an exercise price of $1.12 per share, and will vest over a four-year period, subject to continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
none
-
Rhea-AI Summary

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) will report first-quarter 2024 financial results on May 7, 2024, and host a conference call and webcast. The company focuses on rare immune system diseases, aiming to enhance patient lives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
conferences earnings
-
Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR)has announced the approval of XOLREMDI™ (mavorixafor) capsules by the FDA. The drugis the first of its kind, targeting patients with WHIM syndrome and is the first drug specifically indicated for the condition. The company has been granted a Rare Pediatric Disease Priority Review Voucher (PRV) concurrent with the approvaland the clinical trial resultshave been positive, with XOLREMDItreatment showingimprovementin ANC, ALC, and a reduction in infections for patients with WHIM syndrome. This milestone has been achieved after the successful completion of the 4WHIM Phase 3 clinical trial. The drug is expected to be commercially available for U.S. patients soon through X4's specialty pharmacy partner, PANTHERx® Rare. Along with the drug's approval, X4 has also announced the launch of X4ConnectTM, which will provide support to eligible U.S. patients, including resources and copay assistance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.44%
Tags
Rhea-AI Summary
X4 Pharmaceuticals (Nasdaq: XFOR) issued 1,164,470 inducement awards to new employees under the 2019 Inducement Equity Incentive Plan. Each option has a ten-year term, an exercise price of $1.41 per share, and vests over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
none
-
Rhea-AI Summary
X4 Pharmaceuticals (XFOR) will participate in the Needham 23rd Annual Healthcare Conference and Piper Sandler Spring Biopharma Symposium to showcase advancements in rare disease treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
conferences
-
Rhea-AI Summary
X4 Pharmaceuticals prepares for the possible U.S. approval of mavorixafor for WHIM syndrome with a PDUFA target action date set for April 30, 2024. The company reported financial results for Q4 and full year 2023, highlighting key events and upcoming milestones. X4 expects a transformative year in 2024 with the submission of an NDA for WHIM syndrome treatment, clinical proof of concept for chronic neutropenia, and initiation of a Phase 3 clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.43%
Tags
Rhea-AI Summary
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) will report financial results for Q4 and full year 2023 on March 21, 2024, with a conference call and webcast. Investors can access the call and webcast through the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
conferences earnings
-
Rhea-AI Summary
X4 Pharmaceuticals issues inducement awards to new employees under the 2019 Inducement Equity Incentive Plan. The awards consist of options to purchase 1,524,112 shares of X4's common stock at an exercise price of $0.9710 per share. Each option will vest over a four-year period, with 25% vesting after 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
none
-
Rhea-AI Summary
X4 Pharmaceuticals (Nasdaq: XFOR) issued inducement awards to new employees under the 2019 Inducement Equity Incentive Plan, granting options to purchase 575,942 shares of X4's common stock. The options have a ten-year term with an exercise price of $0.7814 per share, vesting over a four-year period, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
none
Rhea-AI Summary
X4 Pharmaceuticals (Nasdaq: XFOR) announced the presentation of additional preliminary data from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of once-daily oral mavorixafor with or without concurrent treatment with injectable granulocyte-colony stimulating factor (G-CSF) in people diagnosed with idiopathic, cyclic, or congenital neutropenia. The data continue to support the potential of mavorixafor to raise absolute neutrophil counts (ANC) and enable reduction in G-CSF dosing in patients with chronic neutropenia. The trial is expected to initiate in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of X4 Pharmaceuticals (XFOR)?

The current stock price of X4 Pharmaceuticals (XFOR) is $0.58 as of December 24, 2024.

What is the market cap of X4 Pharmaceuticals (XFOR)?

The market cap of X4 Pharmaceuticals (XFOR) is approximately 98.9M.

What does X4 Pharmaceuticals specialize in?

X4 Pharmaceuticals specializes in developing novel therapeutics aimed at improving immune cell trafficking and reversing immune suppression, particularly for treating rare diseases and conditions resulting from immune system dysfunction.

What is mavorixafor?

Mavorixafor is an oral, once-daily small-molecule antagonist of the chemokine receptor CXCR4. It is X4 Pharmaceuticals' lead clinical candidate, currently under FDA priority review for treating WHIM syndrome.

What is WHIM syndrome?

WHIM syndrome is a rare primary immunodeficiency characterized by Warts, Hypogammaglobulinemia, Infections, and Myelokathexis. It involves reduced mobilization and trafficking of white blood cells from the bone marrow.

What are the latest developments for X4 Pharmaceuticals?

X4 Pharmaceuticals recently submitted an NDA for mavorixafor to the FDA, supported by positive Phase 3 trial results. The FDA has accepted the NDA for priority review, with a target decision date set for April 30, 2024.

What other conditions is mavorixafor being investigated for?

Besides WHIM syndrome, mavorixafor is being investigated for treating chronic neutropenic disorders. X4 Pharmaceuticals is planning a Phase 3 clinical program for these conditions.

Where is X4 Pharmaceuticals headquartered?

X4 Pharmaceuticals is headquartered in Boston, Massachusetts, with a research center of excellence located in Vienna, Austria.

Has mavorixafor received any special designations from regulatory bodies?

Yes, mavorixafor has been granted Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Disease Designation in the U.S., and Orphan Drug Status in both the U.S. and the European Union.

What are the promising indications from the 4WHIM Phase 3 clinical trial?

The 4WHIM Phase 3 trial showed that mavorixafor was able to reduce infection rates, increase immune cell counts, and was generally well tolerated without treatment-related serious adverse events.

What other products are in X4 Pharmaceuticals' pipeline?

X4 Pharmaceuticals is developing additional CXCR4 antagonists, including X4P-002 and X4P-003, which are in preclinical stages and designed for different immunological properties and mechanisms.

How can I stay updated on X4 Pharmaceuticals' progress?

You can stay updated by visiting X4 Pharmaceuticals' official website at www.x4pharma.com and subscribing to their news alerts.

X4 Pharmaceuticals, Inc.

Nasdaq:XFOR

XFOR Rankings

XFOR Stock Data

98.92M
155.53M
1.15%
67.66%
6.78%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
BOSTON